Trillium Therapeutics, a wholly-owned subsidiary of Stem Cell Therapeutics, has completed dosing in patients with interstitial cystitis / bladder pain syndrome (IC/BPS) in the Phase I study of TTI-1612.
The safety and tolerability of single ascending doses of TTI-1612, a locally-delivered recombinant growth factor, will be assessed in IC/BPS patients during the study.
TTI-1612 is being developed to correct dysfunction and restore the bladder epithelium to a normal, healthy state.
Stem Cell Therapeutics chief scientific officer Dr Bob Uger said the on-time completion of dosing in the study is a significant early milestone in TTI-1612’s development.
“We are encouraged by our clinical experience to date with this drug, and believe we are setting the groundwork for a partner to move this program forward into Phase II testing,” Uger said.
The study, which enrolled a total of 28 patients at four urology clinics in Southern Ontario, has also evaluated pharmacokinetics and changes in disease symptoms.
According to preliminary data, the drug exhibited a favourable pharmacokinetic profile and is well-tolerated.
The company expects to release the study results soon.
